MIM
AMLX icon

MetLife Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

MetLife Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
55,700
+4,113
+8% +$63.6K ﹤0.01% 1522
2026
Q1 		$717K Buy
51,587
+1,933
+4% +$27.2K ﹤0.01% 1573
2025
Q4 		$600K Buy
49,654
+6,725
+16% +$91.3K ﹤0.01% 1707
2025
Q3 		$583K Hold
42,929
– – ﹤0.01% 1730
2025
Q2 		$275K Buy
+42,929
New +$209K ﹤0.01% 2008
2024
Q2 		– Sell
-13,768
Closed -$39.1K – 2881
2024
Q1 		$39.1K Sell
13,768
-12,944
-48% -$169K ﹤0.01% 2739
2023
Q4 		$393K Hold
26,712
– – ﹤0.01% 1828
2023
Q3 		$489K Hold
26,712
– – ﹤0.01% 1654
2023
Q2 		$576K Hold
26,712
– – ﹤0.01% 1597
2023
Q1 		$784K Hold
26,712
– – 0.01% 1363
2022
Q4 		$987K Buy
26,712
+7,251
+37% +$257K 0.01% 1219
2022
Q3 		$548K Buy
19,461
+12,676
+187% +$316K ﹤0.01% 1576
2022
Q2 		$131K Hold
6,785
– – ﹤0.01% 2579
2022
Q1 		$87.2K Buy
+6,785
New +$153K ﹤0.01% 2638

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

MetLife Investment Management's AMLX Position: Q2 2026 in Review

MetLife Investment Management increased its Amylyx Pharmaceuticals (AMLX) stake by 8% in Q2 2026, buying an estimated $63.6K and bringing the position to 55,700 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

MetLife Investment Management first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • MetLife Investment Management held 55,700 shares of Amylyx Pharmaceuticals worth $1M as of Q2 2026.
  • MetLife Investment Management bought 4,113 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $63.6K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1522 holding.
  • MetLife Investment Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.